Treatment Strategies for Biliary Tract Cancer: A Surgical Perspective from Historical Evolution to Neoadjuvant Therapy [0.03%]
从历史演变至新辅助治疗的胆道癌外科治疗策略的观点分析
Takehiro Okabayashi,Motoyasu Tabuchi,Teppei Tokumaru et al.
Takehiro Okabayashi et al.
Background: Biliary tract cancer (BTC) is an aggressive malignancy with poor prognosis despite curative resection, necessitating multidisciplinary treatment strategies beyond surgery alone. ...
Next-Generation Therapies for Meningioma: Overcoming Barriers and Expanding Treatment Options [0.03%]
脑膜瘤下一代疗法:克服障碍和扩大治疗选择
Shayan Sheikhmiri,Elyas Hasanzadeh,Reza Chaman et al.
Shayan Sheikhmiri et al.
Meningioma is the most common primary brain tumor. Surgical resection and, in some cases, adjuvant radiotherapy remain the cornerstone of treatment, offering an exceptionally high cure rate. However, treatment can be challenging, particular...
Differential Toxicity of Immune Checkpoint Inhibitors in Older Adults: A Large-Scale, Propensity Score-Matched Real-World Analysis [0.03%]
免疫检查点抑制剂在老年人中的差异毒性:一项大型、倾向性评分匹配的真实世界分析
Muhammad Awidi,Muntaser Al Zyoud,Noor S Bader et al.
Muhammad Awidi et al.
Background: The risk-benefit profile of immune checkpoint inhibitors (ICIs) in the understudied elderly population (≥75 years) remains poorly defined. We characterized clinical outcomes and immune-related adverse events ...
Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context [0.03%]
2025年ASCO胃肠肿瘤分会上可能改变实践的临床研究——批判性回顾及临床背景分析
Nabil Ismaili
Nabil Ismaili
The ASCO 2025 meeting featured several phase III trials with the potential to impact gastrointestinal cancer management. CheckMate 577 reported mature overall survival (OS) data for adjuvant nivolumab in esophageal/GEJ cancer; however, OS b...
CTL-NK Signature Based on Immune Gene Profiling and IHC Predicts Clinical Outcomes in Triple-Negative Breast Cancer [0.03%]
基于免疫基因谱和IHC的CTL-NK特征标志物可预测三阴性乳腺癌患者的临床结局
Ahmed J Alfahdawi,Ali Mohammed Sameen,Ashjan Mohammed Hussien et al.
Ahmed J Alfahdawi et al.
Aim: Triple-negative breast cancer (TNBC) lacks targeted therapies and demonstrates heterogeneous outcomes. Tumor-infiltrating lymphocytes (TILs) are candidate prognostic biomarkers that reflect the tumor immune microenvi...
The Influence of Body Mass Index on Treatment Response and Survival in HER2-Positive Breast Cancer Patients [0.03%]
体重指数对HER2阳性乳腺癌患者治疗反应和生存的影响
Andrew Coles,Samantha Robinson,Wyatt DSpain et al.
Andrew Coles et al.
Background: This study sought to examine survival in HER2-positive breast cancer patients based on their BMI. Furthermore, this study investigated the correlations between several other variables such as race, treatment m...
A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science [0.03%]
KRAS p.G12C抑制剂在转移性结直肠癌中的疗效系统评价:当前科学现状
Jeffrey Mathew Boby,Nosakhare Ilerhunmwuwa,Jame Mathew Benny et al.
Jeffrey Mathew Boby et al.
Background: KRAS p.G12C (c.34G > T) inhibitors have been reported to have varying survival outcomes in CRC patients across studies. Hence, our review aimed to provide a comprehensive understanding of the efficacy and safe...
Clinical Characteristics and Prognostic Factors of Renal Sarcoma: A Japanese National Cancer Registry Study [0.03%]
日本国家癌症登记处肾肉瘤的临床特征和预后因素研究
Hiroya Kondo,Koichi Ogura,Chigusa Morizane et al.
Hiroya Kondo et al.
We analyzed survival rates and prognostic factors for renal sarcoma using Japan's National Cancer Registry data. We conducted a retrospective cohort study of patients diagnosed with renal sarcoma (2016-2019). Prognostic factors were evaluat...
Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma [0.03%]
贝伐单抗联合化疗或免疫治疗在晚期/复发卵巢透明细胞癌中肿瘤学结局的系统评价和单组 Meta 分析
Yuling Gu,Yunxian Tang,Cui Zheng et al.
Yuling Gu et al.
The study aimed to evaluate the oncological outcomes related to bevacizumab-based combination therapy among patients with advanced or recurrent ovarian clear cell carcinoma (OCCC). PubMed, Web of Science, Cochrane Library and Embase were se...
Investigation of Adverse Response Expressions to Immune Checkpoint Inhibitor Therapy in PD1-Expressing Non-Small Cell Lung Cancer Patients [0.03%]
程序性死亡受体1表达的非小细胞肺癌患者免疫检查点抑制剂治疗不良反应的调查分析
Bran Yousif Mikaeel,Goran Othman,Abbas Salihi et al.
Bran Yousif Mikaeel et al.
Lung tumor is the leading cause of tumors in global deaths. The determination of the coefficient reflects that 14% of the HBA1C variation was determined by dose, with the remaining variation reverting to other factors influencing HBA1C. The...